Core Viewpoint - The announcement details the unlocking of a portion of pre-IPO shares of Suzhou Haofan Biological Co., Ltd., which will be released from a 24-month lock-up period starting from July 14, 2025, allowing for increased liquidity in the company's stock [1][3]. Group 1: Pre-IPO Share Issuance Overview - The company received approval from the China Securities Regulatory Commission for an initial public offering (IPO) of 27,000,000 shares, which began trading on July 12, 2023 [1]. - Prior to the IPO, the total share capital of the company was 108,000,000 shares, with 23,394,744 shares subject to lock-up, representing 21.66% of the total post-IPO share capital [1]. - The total number of locked shares is 84,605,256, accounting for 78.34% of the total post-IPO share capital [1]. Group 2: Locked Shares Release Details - A total of 1,863,000 shares, representing 1.73% of the total share capital, will be released from lock-up on July 14, 2025 [3]. - The shareholders applying for the release of locked shares include four individuals, who have committed to adhere to lock-up agreements [3][5]. - The company has confirmed that there have been no changes in share capital due to issuance, repurchase, or stock dividends since the IPO [3]. Group 3: Compliance and Commitments - The shareholders have made commitments to not transfer or manage their shares for 12 months post-IPO and to comply with relevant regulations regarding share transfers and reductions [4]. - The shareholders have fulfilled their commitments, ensuring that there are no outstanding obligations affecting the release of locked shares [5]. - The company will monitor compliance with share reduction commitments and disclose shareholder compliance in regular reports [5]. Group 4: Share Capital Structure Changes - Following the release of locked shares, the structure of the company's share capital will change, with locked shares decreasing to 65,895,225, representing 61.01% of the total [5]. - The number of unrestricted shares will increase to 42,104,775, accounting for 38.99% of the total share capital [5]. - The total share capital remains unchanged at 108,000,000 shares [5].
昊帆生物: 部分首次公开发行前已发行股份上市流通提示性公告